CO2022000029A2 - Preparados de prevotella y tratamiento de la enfermedad pulmonar obstructiva crónica (epoc) y otras afecciones pulmonares - Google Patents

Preparados de prevotella y tratamiento de la enfermedad pulmonar obstructiva crónica (epoc) y otras afecciones pulmonares

Info

Publication number
CO2022000029A2
CO2022000029A2 CONC2022/0000029A CO2022000029A CO2022000029A2 CO 2022000029 A2 CO2022000029 A2 CO 2022000029A2 CO 2022000029 A CO2022000029 A CO 2022000029A CO 2022000029 A2 CO2022000029 A2 CO 2022000029A2
Authority
CO
Colombia
Prior art keywords
prevotella
histicola
melaninogenica
copd
treatment
Prior art date
Application number
CONC2022/0000029A
Other languages
English (en)
Inventor
Veena Taneja
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of CO2022000029A2 publication Critical patent/CO2022000029A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona métodos y materiales relacionados con el tratamiento de una afección pulmonar, como la enfermedad pulmonar obstructiva crónica (EPOC), utilizando una composición que contiene Prevotella viva (por ejemplo, P. histicola y/o P. melaninogenica), Prevotella muerta (o inactivada) (por ejemplo, P. histicola y/o P. melaninogenica), componentes de Prevotella (por ejemplo, P. histicola y/o P. melaninogenica), vesículas (por ejemplo, OMVs) de Prevotella (por ejemplo, P. histicola y/o P. melaninogenica), o una combinación de los mismos. Por ejemplo, se proporcionan métodos y materiales para utilizar una composición que contenga Prevotella viva (por ejemplo, P. histicola y/o P. melaninogenica), Prevotella muerta (o inactivada) (por ejemplo, P. histicola y/o P. melaninogenica), componentes de Prevotella (por ejemplo, P. histicola y/o P. melaninogenica), vesículas (por ejemplo, OMVs) de Prevotella (por ejemplo, P. histicola y/o P. melaninogenica), o una combinación de los mismos para tratar una afección pulmonar, como la EPOC.
CONC2022/0000029A 2019-06-17 2022-01-05 Preparados de prevotella y tratamiento de la enfermedad pulmonar obstructiva crónica (epoc) y otras afecciones pulmonares CO2022000029A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962862186P 2019-06-17 2019-06-17
PCT/US2020/038084 WO2020257248A1 (en) 2019-06-17 2020-06-17 Prevotella preparations and treating chronic obstructive pulmonary disease (copd) and other lung conditions

Publications (1)

Publication Number Publication Date
CO2022000029A2 true CO2022000029A2 (es) 2022-04-08

Family

ID=74037580

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0000029A CO2022000029A2 (es) 2019-06-17 2022-01-05 Preparados de prevotella y tratamiento de la enfermedad pulmonar obstructiva crónica (epoc) y otras afecciones pulmonares

Country Status (11)

Country Link
US (1) US20220296657A1 (es)
EP (1) EP3983067A4 (es)
JP (1) JP2022537178A (es)
KR (1) KR20220024466A (es)
CN (1) CN114340732A (es)
AU (1) AU2020295393A1 (es)
BR (1) BR112021025416A2 (es)
CA (1) CA3143597A1 (es)
CO (1) CO2022000029A2 (es)
MX (1) MX2021015711A (es)
WO (1) WO2020257248A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220031765A1 (en) * 2018-11-30 2022-02-03 Ospedale San Raffaele S.R.L. Bacterial strains for medical uses
US20240148797A1 (en) * 2021-02-26 2024-05-09 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
WO2022187064A1 (en) * 2021-03-01 2022-09-09 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023146843A1 (en) * 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023200837A1 (en) * 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2024097250A1 (en) * 2022-10-31 2024-05-10 The Trustees Of Columbia University In The City Of New York Polymeric carrier for probiotics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965787A (en) * 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
CN102755646A (zh) * 2002-07-19 2012-10-31 艾博特生物技术有限公司 TNF α相关疾病的治疗
EP3679798B1 (en) * 2015-02-03 2021-11-17 Mayo Foundation for Medical Education and Research Methods and materials for assessing and treating arthritis
KR20180056419A (ko) * 2015-09-09 2018-05-28 레비비코르 인코포레이션 이종 장기이식을 위한 멀티-형질전환 피그
BR112020004347A2 (pt) * 2017-09-08 2020-09-08 Evelo Biosciences, Inc. vesículas extracelulares de prevotella
US20220031765A1 (en) * 2018-11-30 2022-02-03 Ospedale San Raffaele S.R.L. Bacterial strains for medical uses

Also Published As

Publication number Publication date
CN114340732A (zh) 2022-04-12
EP3983067A4 (en) 2023-06-14
MX2021015711A (es) 2022-02-03
KR20220024466A (ko) 2022-03-03
BR112021025416A2 (pt) 2022-02-22
AU2020295393A1 (en) 2022-01-06
JP2022537178A (ja) 2022-08-24
CA3143597A1 (en) 2020-12-24
WO2020257248A1 (en) 2020-12-24
US20220296657A1 (en) 2022-09-22
EP3983067A1 (en) 2022-04-20

Similar Documents

Publication Publication Date Title
CO2022000029A2 (es) Preparados de prevotella y tratamiento de la enfermedad pulmonar obstructiva crónica (epoc) y otras afecciones pulmonares
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
CY1121874T1 (el) Παραγωγα μονο- ή διυποκατεστημενου ινδολιου ως αναστολεις του αναδιπλασιασμου του ιου του δαγκειου πυρετου
CL2019003309A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019002745A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CY1121972T1 (el) Mono- ή διυποκατεστημενα ινδολια ως αναστολεις του αναδιπλασιασμου του ιου του δαγκειου πυρετου
ECSP18073264A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
CL2019002744A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019002876A1 (es) Síntesis de triterpeno-saponina, intermediarios y combinaciones adyuvantes.
CL2019003294A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CR20160520A (es) Oligómeros y conjugados de oligómeros
CL2018002692A1 (es) Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961)
EA201890722A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге
CL2018001192A1 (es) Análogos de saponina triterpeno
CO2021006308A2 (es) Proteínas f de prefusión del vrs estabilizadas
CL2020000879A1 (es) Análogos de saponina de triterpeno.
EA201791614A1 (ru) Производные индола в качестве ингибиторов репликации вирусов денге
MX2020004785A (es) Proceso para preparar tapinarof.
CL2019003064A1 (es) Análogos de triterperno saponina.
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
EA201991041A1 (ru) Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
CL2019003393A1 (es) Virus oncolíticos y método.